EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Psoriasiform Drug Eruption following Fremanezumab: A Case Report

Kayla Coffman, Madelyn Ross, Emily Saurborn, Ashley Grimmett, Shane Cook

Case Reports in Dermatology · 26.08.2026 · 18 (1) · 668-674

DOI: 10.1159/cde/abvag005 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Dermatology, online erschienen am 26.08.2026. Verfasst von Kayla Coffman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Joan C. Edwards School of Medicine, Marshall University, Huntington, WV, USA. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Calcitonin gene-related peptide (CGRP) inhibitors such as fremanezumab are used for migraine prevention. Although relatively safe, adverse skin reactions after beginning CGRP inhibitors have been reported in the literature. We present a case report on a patient who presented with a psoriasiform drug eruption 2 weeks after beginning fremanezumab. Case Presentation: A 32-year-old female with no prior history of psoriasis had a psoriasiform drug eruption that began 2 weeks after injection of the CGRP inhibitor fremanezumab. The eruption began localized to the injection site and later spread to involve the trunk and extremities. Skin biopsy revealed histologic findings consistent with psoriasiform features. Discontinuation of the CGRP inhibitor led to the resolution of all skin manifestations.

Conclusion

The complex effect of CGRP inhibitors on immune modulation may increase the risk of inflammatory skin reactions. These skin manifestations are important for clinicians to be aware of in patients with and without a history of inflammatory conditions. This case report offers further insight into the possible immune system effects present in inflammatory conditions such as psoriasis.

Schlagwörter

Stichwörter der Autor:innen

Calcitonin gene-related peptide inhibitorsCase reportInflammationPsoriasiform drug eruption

Autor:innen und Institutionen

  • Department of Dermatology, Joan C. Edwards School of Medicine, Marshall University, Huntington, WV, USA.

Zitieren

APA

Coffman, K., Ross, M., Saurborn, E., Grimmett, A., & Cook, S. (2026). Psoriasiform Drug Eruption following Fremanezumab: A Case Report. Case Reports in Dermatology, 18(1), 668-674. https://doi.org/10.1159/cde/abvag005

Vancouver

Coffman K, Ross M, Saurborn E, Grimmett A, Cook S. Psoriasiform Drug Eruption following Fremanezumab: A Case Report. Case Reports in Dermatology. 2026;18(1):668-674. doi:10.1159/cde/abvag005

BibTeX
@article{Coffman2026,
  author = {Coffman, Kayla and Ross, Madelyn and Saurborn, Emily and Grimmett, Ashley and Cook, Shane},
  title = {Psoriasiform Drug Eruption following Fremanezumab: A Case Report},
  journal = {Case Reports in Dermatology},
  year = {2026},
  volume = {18},
  number = {1},
  pages = {668--674},
  doi = {10.1159/cde/abvag005}
}
Kostenlos starten →